Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises... Oncol Ther (2016) 4:257–274 DOI 10.1007/s40487-016-0031-1 ORIGINAL RESEARCH A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models . . . Wafaa Hassan Kenny Chitcholtan Peter Sykes Ashley Garrill Received: July 12, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com EGFR/Her-2 inhibitor (canertinib) and a c-Met ABSTRACT inhibitor (PHA665752) in ovarian cancer cell Introduction: Advanced ovarian cancer is often lines in 3D cell aggregates. a fatal disease as chemotherapeutic drugs have Methods: OVCAR-5 and SKOV-3 ovarian cancer limited effectiveness. Better targeted therapy is cell lines were cultured on a non-adherent needed to improve the survival and quality of surface to produce 3D cell clusters and life for these women. Receptor tyrosine kinases aggregates. Cells were exposed to canertinib including EGFR, Her-2 and c-Met are associated and PHA665752, both individually and in with a poor prognosis in ovarian cancer. combination, for 48 h. The effect on growth, Therefore, the co-activation of these receptors metabolism and the expression/ may be crucial for growth promoting activity. phosphorylation of selective signaling proteins In this study, we explored the effect of associated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

Download PDF
18 pages

Loading next page...
 
/lp/springer-journals/a-combination-of-two-receptor-tyrosine-kinase-inhibitors-canertinib-iGxX4SBIPP
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0031-1
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:257–274 DOI 10.1007/s40487-016-0031-1 ORIGINAL RESEARCH A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models . . . Wafaa Hassan Kenny Chitcholtan Peter Sykes Ashley Garrill Received: July 12, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com EGFR/Her-2 inhibitor (canertinib) and a c-Met ABSTRACT inhibitor (PHA665752) in ovarian cancer cell Introduction: Advanced ovarian cancer is often lines in 3D cell aggregates. a fatal disease as chemotherapeutic drugs have Methods: OVCAR-5 and SKOV-3 ovarian cancer limited effectiveness. Better targeted therapy is cell lines were cultured on a non-adherent needed to improve the survival and quality of surface to produce 3D cell clusters and life for these women. Receptor tyrosine kinases aggregates. Cells were exposed to canertinib including EGFR, Her-2 and c-Met are associated and PHA665752, both individually and in with a poor prognosis in ovarian cancer. combination, for 48 h. The effect on growth, Therefore, the co-activation of these receptors metabolism and the expression/ may be crucial for growth promoting activity. phosphorylation of selective signaling proteins In this study, we explored the effect of associated with

Journal

Oncology and Therapy – Springer Journals

Published: Sep 27, 2016

References

  • Cancer statistics, 2007
    Jemal, A; Siegel, R; Ward, E; Murray, T; Xu, J; Thun, MJ
  • Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
    Dienstmann, R; Dosso, S; Felip, E; Tabernero, J
  • Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non–small-cell lung cancer
    Jänne, PA; Pawel, J; Cohen, RB; Crino, L; Butts, CA; Olson, SS
  • Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
    Vergote, IB; Jimeno, A; Joly, F; Katsaros, D; Coens, C; Despierre, E
  • Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer
    Campos, S; Hamid, O; Seiden, MV; Oza, A; Plante, M; Potkul, RK
  • Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
    Steffensen, KD; Waldstrom, M; Andersen, RF; Olsen, DA; Jeppesen, U; Knudsen, HJ
  • Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells
    Alper, O; Bergmann-Leitner, ES; Bennett, TA; Hacker, NF; Stromberg, K; Stetler-Stevenson, WG
  • Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
    Berchuck, A; Kamel, A; Whitaker, R; Kerns, B; Olt, G; Kinney, R
  • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Engelman, JA; Zejnullahu, K; Mitsudomi, T; Song, Y; Hyland, C; Park, JO
  • High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer
    Davies, S; Holmes, A; Lomo, L; Steinkamp, MP; Kang, H; Muller, CY
  • Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF- dependent and- independent mechanisms
    Matte, I; Lane, D; Laplante, C; Garde Granger, P; Rancourt, C; Piché, A
  • Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance
    Krumbach, R; Schüler, J; Hofmann, M; Giesemann, T; Fiebig, H-H; Beckers, T
  • A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
    Rixe, O; Franco, SX; Yardley, DA; Johnston, SR; Martin, M; Arun, BK
  • A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo
    Christensen, JG; Schreck, R; Burrows, J; Kuruganti, P; Chan, E; Le, P
  • Malignant ascites in ovarian cancer and the role of targeted therapeutics
    Smolle, E; Taucher, V; Haybaeck, J
  • Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer
    Sheid, B
  • c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion
    Sawada, K; Radjabi, AR; Shinomiya, N; Kistner, E; Kenny, H; Becker, AR
  • Expression of c-met is a strong independent prognostic factor in breast carcinoma
    Ghoussoub, RA; Dillon, DA; D’Aquila, T; Rimm, EB; Fearon, ER; Rimm, DL
  • Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
    Calvo, E; Tolcher, AW; Hammond, LA; Patnaik, A; Bono, JS; Eiseman, IA
  • Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors
    Wang, Y; Wang, SKK; Yang, C; Sargeant, AM; Hung, J; Kashida, Y
  • Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer
    Chitcholtan, K; Asselin, E; Parent, S; Sykes, P; Evans, J
  • The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer
    Chitcholtan, K; Sykes, PH; Evans, JJ
  • A three dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro
    Lee, JM; Mhawech-Fauceglia, P; Lee, N; Paranian, LC; Lin, YG; Gayther, SA
  • Resveratrol, Acetyl-resveratrol, and polydatin exhibit antigrowth activity against 3D cell aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines
    Hogg, SJ; Chitcholtan, K; Hassan, W; Sykes, PH; Garrill, A
  • Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer
    Lafky, JM; Wilken, JA; Baron, AT; Maihle, NJ
  • Characteristics of EGFR family-mediated HRG signals in human ovarian cancer
    Campiglio, M; Ali, S; Knyazev, PG; Ullrich, A
  • Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer
    Parrott, JA; Skinner, MK
  • EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
    Loupakis, F; Cremolini, C; Fioravanti, A; Orlandi, P; Salvatore, L; Masi, G
  • Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment
    Kwon, Y; Smith, B; Zhou, Y; Kaufman, M; Godwin, A
  • Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo
    Jiang, HL; Jin, JZ; Wu, D; Xu, D; Lin, GF; Yu, H
  • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Kris, MG; Natale, RB; Herbst, RS; Lynch, TJ; Prager, D; Belani, CP
  • A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a gynaecologic oncology group study
    Schilder, RJ; Sill, MW; Lee, YC; Mannel, RA
  • Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation
    Martin, SAP; Miller, A; Emad, L; Rahmani, M; Walker, T; Mitchell, C
  • The role of irreversible HER family inhibition in the treatment of patients with non small cell lung cancer
    Kwak, E
  • Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis
    Niemann, C; Brinkmann, V; Spitzer, E; Hartmann, G; Sachs, M; Naundorf, H
  • Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia
    Irwin, ME; Nelson, LD; Santiago-O’Farrill, JM; Knouse, PD; Miller, CP; Palla, SL
  • HER2 therapy: small molecule HER-2 tyrosine kinase inhibitors
    Spector, N; Xia, W; El-Hariry, I; Yarden, Y; Bacus, S
  • A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
    Yang, Y; Wislez, M; Fujimoto, N; Prudkin, L; Izzo, JG; Uno, F
  • A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin
    Ma, PC; Schaefer, E; Christensen, JG; Salgia, R
  • Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033
    Dilworth, JT; Wojtkowiak, JW; Mathieu, P; Tainsky, MA; Reiners, JJ; Mattingly, RR
  • PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
    Crosswell, HE; Dasgupta, A; Alvarado, CS; Watt, T; Christensen, JG; De, P
  • Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
    Tang, Z; Du, R; Jiang, S; Wu, C; Barkauskas, DS; Richey, J
  • A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Konner, J; Schilder, RJ; DeRosa, FA; Gerst, SR; Tew, WP; Sabbatini, PJ
  • Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
    Weroha, SJ; Oberg, AL; Ziegler, KLA; Dakhilm, SR; Rowland, KM; Hartmann, LC
  • Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma
    Chun, PY; Feng, FY; Scheurer, AM; Davis, MA; Lawrence, TS; Nyati, MK
  • Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets
    Cho, WC; Roukos, DH
  • CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
    Pivot, X; Manikhas, A; Żurawski, B; Chmielowska, E; Karaszewska, B; Allerton, R